Grinednox-L Capsule is a combination antibiotic formulation containing Amoxycillin 250 mg, Cloxacillin 250 mg, and Lactobacillus 1.7 billion spores per capsule. This synergistic blend is designed to effectively combat a broad spectrum of bacterial infections, particularly those caused by penicillinase-producing staphylococci and other susceptible organisms. Amoxycillin, a semi-synthetic beta-lactam antibiotic, exhibits bactericidal activity by inhibiting bacterial cell wall synthesis, while Cloxacillin, a penicillinase-resistant penicillin, enhances efficacy against beta-lactamase-producing bacteria. The inclusion of Lactobacillus spores serves as a probiotic adjunct, promoting the restoration and maintenance of normal gut flora, which may be disrupted during antibiotic therapy, thereby reducing the risk of antibiotic-associated diarrhea and other gastrointestinal disturbances. Grinednox-L Capsule is indicated for the treatment of respiratory tract infections, skin and soft tissue infections, urinary tract infections, and other susceptible bacterial infections. It should be administered as prescribed by a healthcare professional, with dosage adjusted according to the severity of infection and patient response. Caution is advised in patients with a history of hypersensitivity to penicillins or probiotics. This combination therapy offers a comprehensive approach to managing bacterial infections while supporting gastrointestinal health.